TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06599879

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessments:
Description: Several neuropsychological assessments were carried out during the study (at inclusion and 2 years after inclusion), consisting of :~* parental questionnaires (standard questionnaires and questionnaires specifically drawn up for the trial). The aim of these questionnaires will be to assess the patient's neurocognitive level at different times (before and after radiotherapy treatment).~* patient cognitive tests (½ day face-to-face consultation/assessment with a neuropsychologist specialising in paediatrics, followed by a 30-minute telephone call).~Only for patients having received their radiotherapy treatment at the IUCT-O: a multimodal MRI specific to the study (without injection of contrast product) may be performed at inclusion and 2 years after inclusion.
Study: NCT06597734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Description: Given by SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olutasidenib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedazuridine
Description: Given by PO
Study: NCT06587100

Intervention type: DEVICE
Intervention: Fitbit
Description: Participants will wear Fitbit device

Intervention type: DEVICE
Intervention: Fitbit
Description: Participants will wear Fitbit device

Intervention type: DEVICE
Intervention: Apple HealthKit-based devices
Description: Participants will wear personal device and share data with study team.
Study: NCT05470179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pendulum distalizer
Description: class 2 Angle malocclusion
Study: NCT06655428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial Therman Liquid Ablation (ETLA)
Description: The ETLA System is a minimally invasive bronchoscopic treatment designed to deliver heated normal saline to targeted emphysematous lung regions with hyperinflation to cause tissue ablation and subsequent volume reduction as a means for treating emphysema. The ETLA procedures will be performed under general anesthesia. Each procedure will be limited to treatment in a single lung, with either unilateral or bilateral treatment over the two procedures.
Study: NCT06148012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental implant
Description: Digital panoramic radiographs taken during the patients' treatment periods (T0, T1) were used in the study. Measurements of marginal bone levels on radiographs were performed using the Image J software. The distance between the most coronal part of the implant neck and the most apical part of the defect caused by marginal bone loss was measured.~Fractal analysis (FA) was conducted on panoramic radiographs (OPG) with a size of 2952x1435 pixels and a depth of 32 bits. FA on these radiographs at T0 and T1 times was performed using the box counting method determined by White and Rudolp with the ImageJ program(23).
Study: NCT05842265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self acupressure
Description: patients will do self acupressure
Study: NCT06657729

Intervention type: OTHER
Intervention: Succiometry
Description: Assessement of sucking performance by measuring pressures (suction, crushing) with a succiometer every 10 days. This instrument consists of a standard silicone teat for premature newborns, which is connected via two silicone tubes to pressure micro-sensors. These pressure sensors measure the child's sucking activity on the teat. This activity is characterised by suction and crushing movements. It is a non-nutritive sucking activity (no fluid is delivered). Sucking performance is recorded during a period of calm awakening of the infant and over a period of 5 minutes, and is part of routine care since non-nutritive sucking is a common practice in neonatal unit. The first measurement will be taken in the first week of life and then every 7-10 days until discharge from the neonatal unit.
Study: NCT06657586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular exercises
Description: The exercise was applied in 18 sessions of 6 weeks.The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: The treatment program included coldpack from cold application agent, ultrasound (US) treatment and TENS application from electrotherapy methods.
Study: NCT06656364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esprit BTK System
Description: The Esprit BTK System is a resorbable polymeric scaffold with the everolimus drug and a resorbable polymeric coating mounted on a balloon dilatation catheter.
Study: NCT06656845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genus, a self-management app for patients with knee osteoarthritis
Description: The self-management app (Genus) will include weekly reminders with information videos on knee osteoarthritis and treatment options, exercise videos, quizzes, questionnaires, and a platform for remote monitoring by health professionals.
Study: NCT05489120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of FLAVIS
Description: Patients of the FLAVIS group will recevied FLAVIS products in addition to their diet follow-up.
Study: NCT05552976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mezigdomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Specified dose on specified days
Study: NCT05552976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study: NCT05019495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrOMOTE
Description: This is an opt-out, proactive approach to tobacco treatment by a clinical pharmacy specialist. The pharmacist will call patients and offer an individualized pharmacotherapy prescription. The patient must opt-out for it not to be sent to their pharmacy. The patient will also receive brief motivational interviewing and behavioral counseling from the pharmacist.
Study: NCT06660836

Intervention type: DEVICE
Group type: OTHER
Intervention: Mouthguard
Description: After the participants' records are taken with intraoral scanners, custom mouthguards will be prepared from soft EVA sheets in a dental laboratory setting.

Intervention type: OTHER
Group type: OTHER
Intervention: Performance test
Description: Participants will undergo the Yo-Yo performance test both while using and not using mouthguards prepared with a digital workflow.
Study: NCT06657989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reactive balance training
Description: Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reactive balance training
Description: Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
Study: NCT06437613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Static Stretching exercises for 30 seconds
Description: Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Static Stretching exercises for 60 seconds
Description: Intervention includes Following Tests~1. Passive Hip Flexion Test(PHFT)~2. Straight Leg Raises(SLR)~3. Modified Knee Extension Test(MKET)
Study: NCT03489434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
Study: NCT06151639

Intervention type: PROCEDURE
Intervention: general anesthesia
Description: General anesthesia was performed by muscle relaxant(rocuronium 0,6 mg/kg), opioids(phentanyl 1-2 mcg/kg) and propofol 2mg/kg. Inhation anesthetics and remiphentanyl infusion were used for maintance general anesthesia.

Intervention type: PROCEDURE
Intervention: peripheral nerve blocks
Description: With the help of ultrasonography, at the 2nd rib level, between the fasciae of the pectoralis major and minor muscles at the mid-clavicle level (PECS I block, interpectoral fascial plane block) and at the 4th rib level, at the mid-axillary level, between the fasciae of the pectoralis minor and serratus muscles (PECS II block, pectoroseratal fascial plane block) local anesthesia was applied. In patients who underwent PECS block, a high-frequency linear ultrasonography (Esaote, My LabFive-Genova, Italy) probe and a 50 mm tip insulated needle (echoplex+, Vygon Ecouen-France) were used. 0.200% bupivacaine 15 ml was applied for the PECS I block, and 0.200% bupivacaine 20 ml was applied for the PECS II block, and fascial separation was observed. Sensory control was performed in the breast and axilla area and the patients were taken into surgery.
Study: NCT06657989

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Walking
Description: Overground walking
Study: NCT04848220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temanogrel
Description: Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temanogrel
Description: Participants will receive a single intravenous dose of temanogrel on Day 1 (Day 1 of PCI procedure)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single intravenous dose of temanogrel matching placebo on Day 1
Study: NCT06129071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided block of maxillary nerve
Description: Extraoral ultrasound-guided block of the maxillary nerve will be performed in the examined group using an ultrasound device and local anesthetic levobupivacaine (0,5%, 2 mL) combined with triamcinolonacetonid (2mL).
Study: NCT05838105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: 125 mcg once at the day mentioned

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: dose as mentioned

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 100Mg Vag Tab
Description: dose as mentioned
Study: NCT06659757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIT2014
Description: KIT2014 will be administered by inhalation with a nebuliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIT2014
Description: KIT2014 will be administered by inhalation with a nebuliser

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by inhalation with a nebuliser

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by inhalation with a nebuliser
Study: NCT05576883

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Transdiagnostic emotion regulation intervention
Description: The intervention under study includes 5 therapeutic approaches, namely: Positive psychology \[PP\], Mindfulness, Acceptance and Commitment Therapy \[ACT\], Breathing and relaxation, and Self-compassion \[SC\].~The intervention consists of 4 core features:~(i) monitoring through filling in EMAs assessing participants emotional states~(ii) feedback through visualization of participant emotional states upon every completion of the EMAs~(iii) exercises targeting different emotion regulation skills \[i.e., upregulation of positive affect, mindfulness, cognitive defusion, breathing and relaxation, self-compassion) and health facts (i.e., control intervention) describing health information including nutrition, exercise, sleeping habits.~(iv) psychoeducative articles describing the 5 therapeutic approaches (PP, ACT, Mindfulness, Breathing and Relaxation, SC)
Study: NCT05340829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with lymphoma and lympholeukemia
Study: NCT05212389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femicept
Description: 150 μg levonorgestrel +30 μg ethinylestradiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04867174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Financial incentives
Description: Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Convenient scheduling link
Description: In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Convenient scheduling link
Description: In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Convenient scheduling link
Description: In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Convenient scheduling link
Description: In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Race concordant
Description: Randomized to a messenger who is race concordant with the participant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Race concordant
Description: Randomized to a messenger who is race concordant with the participant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender concordant
Description: Randomized to a messenger who is gender concordant with the participant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender concordant
Description: Randomized to a messenger who is gender concordant with the participant
Study: NCT05204082

Intervention type: DEVICE
Group type: OTHER
Intervention: Single Use Vein Entry Indicator Device
Description: Electronic pressure sensing device, integrated to a conventional needle catheter, and which indicates continuously during intravenous cannulation whether the tip of the needle is inside or outside of a vein, to assist a clinician in intravenous cannulation.
Study: NCT05540704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iACT
Description: Treatment is based on Acceptance and Commitment Therapy (ACT), a contemporary cognitive behavioral therapy (CBT) that improves human functioning and adaptability by increasing psychological flexibility. Individual therapy sessions are paired with mobile phone delivered interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care for problems in Type 1 diabetes management
Study: NCT05583305

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging assessment
Description: Investigators shall perform cranial MRI examinations. The scanning protocol will employ an MRI scan protocol with T1-weighted, T2-weighted, FLAIR, susceptibility weighted imaging, diffusion weighted imaging, and time-of-flight magnetic resonance angiography (MRA) sequences. In addition, high-resolution magnetic resonance vessel wall imaging (HRMRI) allows assessment of the vessel wall using specific the SPACE sequence and the MATCH sequence. Assessors of the HRMRI images shall be blinded to the group allocation and clinical information.

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging assessment
Description: Investigators shall perform cranial MRI examinations. The scanning protocol will employ an MRI scan protocol with T1-weighted, T2-weighted, FLAIR, susceptibility weighted imaging, diffusion weighted imaging, and time-of-flight magnetic resonance angiography (MRA) sequences. In addition, high-resolution magnetic resonance vessel wall imaging (HRMRI) allows assessment of the vessel wall using specific the SPACE sequence and the MATCH sequence. Assessors of the HRMRI images shall be blinded to the group allocation and clinical information.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurosonology assessment
Description: Investigators shall perform carotid duplex ultrasonography (CD) assessment, focusing on the peak systolic (PSV) and end diastolic velocity (EDV) of bilateral extracranial internal carotid arteries (ICA) Brightness mode imaging shall gauge the intimal thickness and plaque characteristics (if any) of bilateral ICAs.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurosonology assessment
Description: Investigators shall perform carotid duplex ultrasonography (CD) assessment, focusing on the peak systolic (PSV) and end diastolic velocity (EDV) of bilateral extracranial internal carotid arteries (ICA) Brightness mode imaging shall gauge the intimal thickness and plaque characteristics (if any) of bilateral ICAs.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Test
Description: Nine milliliters of EDTA blood will be drawn during the research clinic visit for evaluation of the degree of neurovascular inflammation. Serum plasminogen activator inhibitor-1 (PAI-1) and high-sensitive C-reactive protein (hsCRP) are markers of vascular inflammation, atherosclerosis, and thrombotic risk. Serum neurofilament light chain (NfL) is a biomarker for neuroaxonal injury that correlates with small vessel disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Test
Description: Nine milliliters of EDTA blood will be drawn during the research clinic visit for evaluation of the degree of neurovascular inflammation. Serum plasminogen activator inhibitor-1 (PAI-1) and high-sensitive C-reactive protein (hsCRP) are markers of vascular inflammation, atherosclerosis, and thrombotic risk. Serum neurofilament light chain (NfL) is a biomarker for neuroaxonal injury that correlates with small vessel disease.
Study: NCT05853744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lavender essential oil inhaled using cotton balls
Description: cotton balls impregnated with 3 drops of lavender essential oil inhaled from a distance of 10 cm during 20 minutes and pure oxygen administered through a face mask.
Study: NCT06347068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9-CAR.B7-H3 T Cell Therapy
Description: iC9-CAR.B7-H3 T cells will then be administered intravenously
Study: NCT05853744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lavender essential oil inhaled using face mask
Description: These three drops were already diluted by five milliliters of distilled water and were sprayed in the area by a nebulizer throughout a face mask. A cotton ball soaked with water was put 10 cm next to the patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: inhaled five milliliters of distilled water in the same way as the patients in the experimental group and also cotton balls with 3 drops of water are placed near the patient.
Study: NCT03609320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The STOP-HPV Trial 5: Bundle Intervention
Description: This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
Study: NCT06552013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MERV 13 filter
Description: This is an environmental intervention consisting of a low-cost box fan with a MERV 13 filter placed behind it. The company Lasko makes these fans and other environmental appliances.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham filter
Description: This is an environmental intervention consisting of a low-cost box fan with a sham filter (MERV 1) placed behind it. The company Lasko makes these fans and other environmental appliances.
Study: NCT05501990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health intervention based on intelligent applet
Description: Patients are jointly managed by a MDT team based on the applet. The supportive intervention based on the applet mainly includes three parts: Nutrition, psychology, and patient management which includes four main parts: Cancer patient education, self-management, patient community, and real-time communication.
Study: NCT05260580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention: Routine care
Study: NCT05248802

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo caplet of DLBS2411
Description: 1 caplet of placebo DLBS2411, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS2411
Description: 1 caplet of DLBS2411 250 mg, twice daily
Study: NCT06216665

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Insulin administration during hyperinsulinemic euglycemic clamp test
Description: Participants will receive insulin delivered continuously during the hyperinsulinemic euglycemic clamp test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test
Description: Participants will receive insulin delivered every five minutes during the hyperinsulinemic euglycemic clamp test